Trial
NCT03425006
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
Itacitinib
Why stopped
Administrative reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-13